Patients with GSDIa need to constantly eat cornstarch to avoid dangerous drops in blood sugar
— Patients with GSDIa need to constantly eat cornstarch to avoid dangerous drops in blood sugar
by Ian Ingram, Managing Editor, MedPage Today
August 20, 2026
• 2 min read
The FDA on Wednesday granted accelerated approval to pariglasgene brecaparvovec (Genglycos) as the first treatment for glycogen storage disease type Ia (GSDIa), an inherited metabolic disorder that requires frequent consumption of cornstarch to prevent severe or life-threatening hypoglycemia.
FDA approves first gene therapy to treat glycogen storage disease type Ia
Ultragenyx's gene therapy gets FDA OK for glycogen storage disorder
Ultragenyx, after FDA speed bump, lands 1st gene therapy nod with green light in glycogen storage disease
Ultragenyx Nabs FDA Nod for First Gene Therapy - Ultragenyx Pharmaceutical (NASDAQ:RARE)
FDA approves Pasatru to reduce lesions, flare-ups in fibrodysplasia ossificans progressiva
Regeneron drug for disease that causes dangerous bone growth earns FDA approval
The FDA has granted accelerated approval of a gene therapy to treat children and adults aged at least 8 years with glycogen…
FDA grants Ultragenyx's Genglycos accelerated approval, its first gene therapy, for GSDIa in patients 8 and up; list price $2.7M.
Sanofi has received a priority review from the FDA for its NDA for venglustat, an oral GCSi intended for the treatment of type 3…
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell…
If at first you don’t succeed in gene therapy, then try, try again. | If at first you don’t succeed in gene therapy, then try,…
The U.S. Food and Drug Administration announced the approval of the first hematopoietic stem cell transplant therapy to treat…
